Blog: A do-it-yourself treatment program for cancer survivors
March 22, 2011
Blog: Hair, Glorious Hair
March 22, 2011 – Kathy LaTour
Words of Wisdom
March 21, 2011
Chilling Hair News
March 21, 2011 – Kathy LaTour
Videos from Yoga Bear
March 21, 2011
JourneyForward.org
March 16, 2011 – Elizabeth Whittington
Herb Could Work Against Advanced Breast Cancer
March 16, 2011 – Kathy LaTour
Transplants More Effective for Young Adults with AML
March 15, 2011 – Elizabeth Whittington
Predicting Colorectal Cancer Recurrence
March 15, 2011 – Elizabeth Whittington
Yoga by Any Other Name
March 03, 2011
Cancer: The Change I Cherish
March 11, 2011
CA-125: What the Numbers Tell Us
March 03, 2011 – Lindsay Ray
Origins of Ovarian Cancer
March 03, 2011 – Renée Twombly
A Primer on How Faster Approval Works
March 03, 2011 – Mike King
Reclaim Your Brain
March 03, 2011 – Staff Reports
The Legal Side of Chemobrain
March 03, 2011 – Kathy LaTour
Mining Cancer Data in the Molecular Age
March 03, 2011 – Mike King
Expecting the Unexpected
March 03, 2011 – Don Vaughan
Bending the Rules
March 03, 2011 – Claudia M. Caruana
Sifting
March 03, 2011 – Janet Filips
The Emperor of All Maladies: A Biography of Cancer
March 03, 2011 – Kathy LaTour
Q & A: Medicare and Advance Care Planning
March 03, 2011 – Len Lichtenfeld, MD
Know Your Rights
March 03, 2011
Favre Visits Pediatric Patient
March 03, 2011 – Lindsay Ray
Jumping on the Ban Wagon
March 03, 2011 – Lindsay Ray
Pipeline
March 03, 2011 – Staff Reports
The Fragile Bonds of Cancer
March 02, 2011 – Richard C. Frank
The Machine and Me
March 02, 2011 – Ginny Vroblesky
A Mouth Full
March 02, 2011 – Lacey Meyer
Overhauling Clinical Trials
March 02, 2011 – Laura Beil
Hitting Hard-to-Treat Cancers
March 02, 2011 – Mike King
Fighting Back
March 02, 2011 – Lindsay Ray
Letters From Our Readers
March 14, 2011
What is the Benefit, Precisely?
March 02, 2011 – Debu Tripathy, MD
Breaking Out of the Silence
March 02, 2011 – Renée Twombly
Hurdles on the Faster Track
March 02, 2011 – Mike King
Lifting the Fog on Chemobrain
March 02, 2011 – Elaine Schattner, MD
Blog: A do-it-yourself treatment program for cancer survivors
March 22, 2011
Blog: Hair, Glorious Hair
March 22, 2011 – Kathy LaTour
Words of Wisdom
March 21, 2011
Chilling Hair News
March 21, 2011 – Kathy LaTour
Videos from Yoga Bear
March 21, 2011
JourneyForward.org
March 16, 2011 – Elizabeth Whittington
Herb Could Work Against Advanced Breast Cancer
March 16, 2011 – Kathy LaTour
Transplants More Effective for Young Adults with AML
March 15, 2011 – Elizabeth Whittington
Currently Viewing
Predicting Colorectal Cancer Recurrence
March 15, 2011 – Elizabeth Whittington
Cancer: The Change I Cherish
March 11, 2011
CA-125: What the Numbers Tell Us
March 03, 2011 – Lindsay Ray
Origins of Ovarian Cancer
March 03, 2011 – Renée Twombly
A Primer on How Faster Approval Works
March 03, 2011 – Mike King
Reclaim Your Brain
March 03, 2011 – Staff Reports
The Legal Side of Chemobrain
March 03, 2011 – Kathy LaTour
Mining Cancer Data in the Molecular Age
March 03, 2011 – Mike King
Expecting the Unexpected
March 03, 2011 – Don Vaughan
Bending the Rules
March 03, 2011 – Claudia M. Caruana
Sifting
March 03, 2011 – Janet Filips
The Emperor of All Maladies: A Biography of Cancer
March 03, 2011 – Kathy LaTour
Q & A: Medicare and Advance Care Planning
March 03, 2011 – Len Lichtenfeld, MD
Know Your Rights
March 03, 2011
Favre Visits Pediatric Patient
March 03, 2011 – Lindsay Ray
Jumping on the Ban Wagon
March 03, 2011 – Lindsay Ray
Pipeline
March 03, 2011 – Staff Reports
The Fragile Bonds of Cancer
March 02, 2011 – Richard C. Frank
The Machine and Me
March 02, 2011 – Ginny Vroblesky
A Mouth Full
March 02, 2011 – Lacey Meyer
Overhauling Clinical Trials
March 02, 2011 – Laura Beil
Hitting Hard-to-Treat Cancers
March 02, 2011 – Mike King
Fighting Back
March 02, 2011 – Lindsay Ray
Letters From Our Readers
March 14, 2011
What is the Benefit, Precisely?
March 02, 2011 – Debu Tripathy, MD
Breaking Out of the Silence
March 02, 2011 – Renée Twombly
Hurdles on the Faster Track
March 02, 2011 – Mike King
Lifting the Fog on Chemobrain
March 02, 2011 – Elaine Schattner, MD

Predicting Colorectal Cancer Recurrence

ColoPrint gene assay can help guide treatment options for some colorectal patients, study shows. 

BY Elizabeth Whittington
PUBLISHED March 15, 2011

In a recent study, a test called ColoPrint accurately identified risk of recurrence in stage 2 colon cancer patients. The test, which examines the expression of 18 genes, could help patients and their medical teams decide on whether chemotherapy is needed after surgery. 

Most stage 2 patients are cured by surgery alone, but about 20 to 30 percent eventually develop distant metastases. Although stage 1 patients generally just undergo surgery and stage 3 patients may have surgery and adjuvant therapy, the benefits of treatment of stage 2 patients are more uncertain.

Currently, risk of recurrence for these patients is determined by certain characteristics of the patient and tumor, such as age, gender, tumor size, biomarkers and whether the cancer has spread to the lymph nodes, but it’s often not enough to make a reliable prognosis.

The ColoPrint study included 233 patients with stage 2 or stage 3 disease. The data, released at the Gastrointestinal Cancers Symposium in late January, showed stage 2 patients who were deemed to be at high risk (approximately 27 percent of the 135 patients with stage 2 disease in the study) had an 80.5 percent chance of distant metastases at five years compared with 95 percent of patients at low risk. Of the 27 percent who were identified at high risk, 20 percent had a recurrence. Five percent of patients who were identified as low risk had a recurrence.

The importance of these findings is that patients who are identified as low risk for recurrence could be spared chemotherapy. However, the test does not identify which high-risk patients would ultimately benefit from chemotherapy.

During a press conference at the meeting, lead author of the study, Robert Rosenberg, MD, PhD, surgeon and assistant professor at the University Hospital at Technical University in Munich, Germany, said, “What is immediately clear […] is that none of the clinical factors are significantly correlated with the development of distant metastases in our study, while ColoPrint does show compelling statistical significance.”

The maker of the ColoPrint gene signature test also developed MammaPrint, the molecular diagnostic test that predicts distant recurrence risk of certain types of breast cancer. ColoPrint is the second such gene test to look at recurrence risk in colon cancer. Another gene signature assay, Oncotype DX Colon Cancer Assay became available early last year, but does not require fresh tissue—one potential drawback to the ColoPrint test, experts say.

Two other ColoPrint clinical trials are in the works. One, an evaluation called PARSC (Prospective study for the Assessment of Recurrence risk in Stage II CC patients using ColoPrint), is aiming to complete enrollment of 600 stage 2 patients and expects interim results later this year, while another study examines ColoPrint in stage 3 patients.

Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Colorectal Cancer CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In